Defining the optimal type and timing of COVID-19 vaccine in pregnancy
Defining the optimal type and timing of COVID-19 vaccine in pregnancy
批准号:
10553715
负责人:
Ai-ris Yonekura Collier
金额:
$25.94万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-21 至 2024-12-31
关键词:
2019-nCoVAddressAffectAgeAntibodiesAntibody ResponseAntibody titer measurementBloodBrazilCOVID-19COVID-19 vaccinationCOVID-19 vaccineCesarean sectionClinicalClinical TrialsCritical IllnessCytomegalovirusDataEmergency SituationEnrollmentFutureGestational AgeGoalsHealthHuman MilkHypertensionImmuneImmune responseImmunologicsImmunosuppressionIndividualInfantInfectionInflammatoryInfluenzaInterferonsKnowledgeLactationLate pregnancyLeadMaternal antibodyMaternally-Acquired ImmunityMeasuresMechanical ventilationMissionModerna COVID-19 vaccineMothersNeonatalNewborn InfantPassive ImmunityPatientsPersonsPfizer-BioNTech COVID-19 vaccinePlacentaPostpartum PeriodPregnancyPremature BirthPublic HealthPublishingRecommendationReportingResearchRespiratory syncytial virusRiskSARS-CoV-2 antibodySARS-CoV-2 infectionSerious Adverse EventSignal TransductionSmall for Gestational Age InfantStreptococcus Group BT cell responseT-LymphocyteUmbilical Cord BloodUnited StatesUnited States National Institutes of HealthVaccinatedVaccinationVaccineeVaccinesViralViral VectorWomanWorkZika Virusadverse pregnancy outcomeantibody transferarmcellular developmentdesignearly pregnancyemerging pathogenhigh riskimmunogenicityimplantationimprovedinfant deathinnovationmaternal immune systemmaternal outcomematernal vaccinationneonatal outcomeneonateneutralizing antibodynovel vaccinespathogenplacental transferpregnantpreventreproductivetrial comparingvaccination strategyvaccine developmentvaccine efficacyvaccine evaluationvaccine platformvaccine responsevaccine strategyvaccine-induced antibodiesvaccine-induced immunity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Pregnant individuals are more likely to require invasive mechanical ventilation or die from complications related
to coronavirus disease 2019 (COVID-19) than non-pregnant women. COVID-19 vaccination in pregnancy can
prevent the consequences of infection for the mother and provide passive immunity to newborns through
placental transfer of vaccine-induced antibodies. The maternal immune system undergoes adaptive changes
during pregnancy characterized by both active suppression of immune responses against the developing
pregnancy and pro-inflammatory signals to promote healthy implantation and initiate labor. The central
hypothesis is that the adaptive immunologic changes in pregnancy lead to differences in the development of
vaccine-induced immunity depending on the gestational age at vaccination and/or the vaccine platform used.
The overall objective of this proposal is to address important knowledge gaps including limited information
regarding cellular immune responses following maternal vaccination, immune responses after vaccination in
early pregnancy, and comparison of immunogenicity across different vaccine platforms. The research proposed
is innovative because we will use a comprehensive immune profiling approach to quantify functional cellular and
antibody responses in order to define the COVID-19 vaccine type and timing that optimizes robust and durable
maternal vaccine-induced immunity (Aim 1) and neonatal passive immunity from placental transfer of viral
neutralizing antibody (Aim 2). The proposed research is significant because it is expected to provide data to
inform clinical recommendations for COVID-19 vaccines in pregnancy to improve maternal and neonatal
outcomes. The long-term goal will be to provide preliminary data for a larger study evaluating vaccine efficacy
for pregnant individuals and their neonates. The knowledge provided by this proposal will also inform future
vaccine development for other important and emerging pathogens in pregnancy.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Defining the optimal type and timing of COVID-19 vaccine in pregnancy
-
批准号:10433615
-
项目类别:
-
资助金额:$21.61万
-
财政年份:2022
-
负责人:Ai-ris Yonekura Collier
-
依托单位:
海外基金